Mark C. Mc Kenna Net Worth

The estimated Net Worth of Mark C. Mc Kenna is at least $368 Tausend dollars as of 19 August 2019. Mark Kenna owns over 10,773 units of Bausch Health Companies Inc stock worth over $132,423 and over the last 6 years Mark sold BHC stock worth over $235,175.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Kenna BHC stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Bausch Health Companies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Mark sold 10,773 units of BHC stock worth $235,175 on 19 August 2019.

The largest trade Mark's ever made was selling 10,773 units of Bausch Health Companies Inc stock on 19 August 2019 worth over $235,175. On average, Mark trades about 1,796 units every 0 days since 2019. As of 19 August 2019 Mark still owns at least 20,756 units of Bausch Health Companies Inc stock.

You can see the complete history of Mark Kenna stock trades at the bottom of the page.

What's Mark Kenna's mailing address?

Mark's mailing address filed with the SEC is 400 SOMERSET CORPORATE BLVD., , BRIDGEWATER, NJ, 08807.

Insiders trading at Bausch Health Companies Inc

Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas und Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.

What does Bausch Health Companies Inc do?

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###

Complete history of Mark Kenna stock trades at Bausch Health Companies Inc

Bausch Health Companies Inc executives and stock owners

Bausch Health Companies Inc executives and other stock owners filed with the SEC include:

• Joseph Papa,
  Chairman of the Board, Chief Executive Officer
• Paul Herendeen,
  Chief Financial Officer, Executive Vice President
• Joseph C. Papa,
  CEO & Chairman
• Thomas Appio,
  President & Co-Head Bausch + Lomb/International
• William Humphries,
  
• Christina Ackermann,
  Executive Vice President, General Counsel
• Thomas J. Appio,
  Pres & Co-Head Bausch + Lomb/International
• Paul S. Herendeen,
  Exec. VP and Advisor to Chairman & CEO
• Joseph Gordon,
  President & Co-Head Bausch + Lomb/International
• Christina M. Ackermann,
  Exec. VP, Gen. Counsel & Head of Commercial Operations
• Thomas Ross,
  Lead Independent Director
• Russel Robertson,
  Independent Director
• Robert Power,
  Independent Director
• Argeris Karabelas,
  Independent Director
• Sarah Kavanagh,
  Independent Director
• D. Robert Hale,
  Independent Director
• Amy Wechsler,
  Independent Director
• Richard De Schutter,
  Independent Director
• Andrew Charles von Eschenbach,
  Independent Director
• John Paulson,
  Independent Director
• Tom G. Vadaketh,
  Chief Financial Officer
• Frederick J. Munsch,
  Controller & Chief Accounting Officer
• Kelly Webber,
  Sr. VP & Chief HR Officer
• Stacey Williams,
  VP of Marketing
• Michael McMyne,
  VP of Sales
• Arthur J. Shannon,
  Sr. VP and Head of Investor Relations & Communications
• Dr. Robert F. Butz,
  VP of Medical & Scientific Affairs
• Osama A. Eldessouky,
  CFO & Exec. VP
• Christian A Garcia,
  Director
• Frank D. Lee,
  Director
• Mark C. Mc Kenna,
  President, Salix
• Holdings, L.P.Value Act Hol...,
  
• Brett Icahn,
  Director
• Steven D Miller,
  Director
• Tom George Vadaketh,
  EVP, Chief Financial Officer
• Holdings, L.P.Value Act Cap...,
  
• Aimee J. Lenar,
  EVP, US Pharma
• Seana Carson,
  EVP, General Counsel
• David Robert Value Act Hold...,
  
• Sam Eldessouky,
  EVP & Chief Financial Officer
• Frederick Munsch,
  SVP, Controller and CAO
• Robert Spurr,
  President, U.S. Businesses
• Richard Mulligan,
  Director
• John S Barresi,
  SVP, Controller & CAO
• Jean Jacques Charhon,
  EVP, CFO